Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial
- PMID: 34480862
- PMCID: PMC8409093
- DOI: 10.1016/S2213-2600(21)00358-1
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial
Conflict of interest statement
JS reports personal fees from Vaccitech, Heat Biologics, Eli Lilly, Alveo Technologies, Agenus, Equilibre Biopharmaceuticals, Graviton Bioscience Corporation, Greenmantle, Zedsen, BenevolentAI, Lansdowne Partners, Vitruvian, BB Healthcare Trust PLC, and Celltrion; lecture fees from Eli Lilly; and advisory board participation (without fees) for Pear Bio, Certis Oncology Solutions, Bryologyx, the College of Experts for the DHSC/UKRI Global Effect on COVID-19 Health Research funding opportunity, and Volvox, all outside of the submitted work. JS is also on the board of directors for Xerion (without fees); and is the co-editor-in-chief of Oncogene (with stipend received from Springer Nature), outside of the submitted work. ACK declares no competing interests.
Comment on
-
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.Lancet Respir Med. 2021 Dec;9(12):1407-1418. doi: 10.1016/S2213-2600(21)00331-3. Epub 2021 Sep 1. Lancet Respir Med. 2021. PMID: 34480861 Free PMC article. Clinical Trial.
References
-
- Kalil AC, Johnson DW, Lisco SJ, Sun J. Early goal-directed therapy for sepsis: a novel solution for discordant survival outcomes in clinical trials. Crit Care Med. 2017;45:607–614. - PubMed
-
- Kalil AC, Syed A, Rupp ME, et al. Is bacteremic sepsis associated with higher mortality in transplant recipients than in nontransplant patients? A matched case-control propensity-adjusted study. Clin Infect Dis. 2015;60:216–222. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources